Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/30261
Başlık: Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/Akciğer Hastalıkları Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.
0000-0003-3604-8826
Dilektaşlı, Aslı Görek
Çetinoğlu, Ezgi Demirdoğen
Uzaslan, Esra
Budak, Ferah
Coşkun, Funda
Ursavaş, Ahmet
Ercan, İlker
Ege, Ercüment
AAD-1271-2019
F-4657-2014
AAI-3169-2021
AAI-1004-2021
ABF-2367-2020
36466376600
57189524206
8761653500
6701913697
21734137500
8329319900
6603789069
6701341320
Anahtar kelimeler: Respiratory system
COPD
Frequent exacerbator
Hospitalized exacerbation
PARC/(CCL-18)
Obstructive pulmonary-disease
Systemic inflammation
Lung-function
Biomarkers
Frequency
CCL18
Macrophages
Validation
Phenotypes
Dyspnea
Yayın Tarihi: 2017
Yayıncı: Dove Medical
Atıf: Dilektaşlı, A. G. vd. (2017). ''Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization''. International Journal of COPD, 12, 199-208.
Özet: Introduction: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization. Materials and methods: Clinically stable COPD patients and participants with smoking history but normal spirometry (NSp) were recruited for the study. Modified Medical Research Council Dyspnea Scale, COPD Assessment Test, spirometry, and 6-min walking test were performed. Serum CCL-18 levels were measured with a commercial ELISA Kit. Results: Sixty COPD patients and 20 NSp patients were recruited. Serum CCL-18 levels were higher in COPD patients than those in NSp patients (169 vs 94 ng/mL, P, 0.0001). CCL-18 level was significantly correlated with the number of exacerbations (r=0.30, P=0.026), although a difference in CCL-18 values between infrequent and frequent exacerbator COPD (168 vs 196 ng/mL) subgroups did not achieve statistical significance (P=0.09). Serum CCL-18 levels were significantly higher in COPD patients who had experienced at least one exacerbation during the previous 12 months. Overall, ROC analysis revealed that a serum CCL-18 level of 181.71 ng/mL could differentiate COPD patients with hospitalized exacerbations from those who were not hospitalized with a 88% sensitivity and 88.2% specificity (area under curve: 0.92). Serum CCL-18 level had a strong correlation with the frequency of exacerbations requiring hospitalization (r=0.68, P, 0.0001) and was found to be an independent risk factor for hospitalized exacerbations in the multivariable analysis. Conclusion: CCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores.
URI: https://www.dovepress.com/getfile.php?fileID=34330
https://doi.org/10.2147/COPD.S118424
http://hdl.handle.net/11452/30261
ISSN: 1178-2005
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Dilektaşlı_vd_2017.pdf1.08 MBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons